Kenvue Inc. (KVUE)
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
- Symbol
- KVUE
- Exchange
- NYSE
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Market cap
- $34.30B
- 52 week range
- 14.02 - 20.13
Valuation
- Share price
- $17.67 (close of 2026-09-23)
- P/E (TTM)
- 20.53x
- Price to book
- 3.25x
- Price to free cash flow
- 17.92x
- Enterprise value
- $41.80B
- Book value per share
- $5.50
Price performance
| Period | Change |
|---|
| 1 day | 0.00% |
| 5 days | -1.40% |
| 1 month | -7.29% |
| 3 months | -4.02% |
| 6 months | +0.40% |
| Year to date | +2.43% |
| 1 year | +2.49% |
| 3 years | -14.01% |
| All time | -34.31% |
Profitability and growth
- Return on equity
- 13.66%
- Return on invested capital
- 10.26%
- Return on assets
- 5.43%
- Return on capital employed
- 11.42%
- Gross margin
- 58.13%
- Net margin
- 9.72%
- EBITDA margin
- 19.64%
- Revenue growth
- -2.14%
- Net income growth
- 42.72%
- Free cash flow growth
- 28.99%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.58%
- Current ratio
- 1.01x
- Net debt to EBITDA
- 2.33x
Latest reported year
- Period end
- 2025-12-28
- Fiscal year
- 2025
- Revenue
- $15.12B
- Cost of revenue
- $6.33B
- Gross profit
- $8.79B
- EBITDA
- $2.97B
- Net income
- $1.47B
- Earnings per share
- $0.77
- Research and development
- $382.00M
- Shares outstanding
- 1.92B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-28 | $15.12B | $8.79B | $1.47B | $0.77 |
| 2024-12-29 | $15.46B | $8.96B | $1.03B | $0.54 |
| 2023-12-31 | $15.44B | $8.64B | $1.66B | $0.90 |
| 2023-01-01 | $14.95B | $8.29B | $2.06B | $1.20 |
| 2022-01-02 | $15.05B | $8.42B | $2.08B | $1.21 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-28 | 58.13% | 9.72% | 13.66% | 10.26% |
| 2024-12-29 | 57.97% | 6.66% | 10.65% | 8.41% |
| 2023-12-31 | 55.96% | 10.77% | 14.84% | 10.88% |
| 2023-01-01 | 55.42% | 13.81% | 10.34% | 11.15% |
| 2022-01-02 | 55.93% | 13.80% | 10.14% | 10.50% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-28 | $1.06B | - |
| 2024-12-29 | $1.07B | - |
| 2023-12-31 | $1.38B | $7.69B |
| 2023-01-01 | $1.23B | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-28 | $1.72B | $136.00M |
| 2024-12-29 | $1.33B | $254.00M |
| 2023-12-31 | $2.70B | $188.00M |
| 2023-01-01 | $2.15B | $137.00M |
| 2022-01-02 | $39.00M | $141.00M |
Dividend history
- Most recent payment
- 2026-09-21
- Paid in the last twelve months
- $1.04
| Payment date | Dividend per share |
|---|
| 2026-09-21 | $0.21 |
| 2026-08-12 | $0.21 |
| 2026-05-13 | $0.21 |
| 2026-02-11 | $0.21 |
| 2025-11-12 | $0.21 |
| 2025-08-13 | $0.21 |
| 2025-05-14 | $0.20 |
| 2025-02-12 | $0.20 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-02
- Consensus EPS estimate
- $0.28
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.32 |
| 2026-05-07 | - | - |
| 2026-02-17 | - | - |
| 2025-11-03 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-06 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- kenvue.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Procter & Gamble Co (PG) · Colgate-Palmolive Co (CL) · Estee Lauder Companies Inc (EL) · Kimberly-Clark Corp (KMB) · Church & Dwight Co Inc (CHD) · Clorox Co (CLX) · Constellation Brands, Inc. (STZ) · Molson Coors Beverage Co (TAP)
All Consumer Defensive companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades